Treatment of vulvar intraepithelial neoplasia (VIN) with local bleomycin.
Surgical management of vulvar intraepithelial neoplasia has resulted in frequent failure or poor patient acceptance. Bleomycin (NSC 125066-Blenoxane, Bristol Laboratories), with its activity against squamous neoplasms, provides an ideal drug for use in the medical management of this disease. Twelve patients were treated with topical and/or intradermal bleomycin. None of those treated topically and only 2 of 10 treated intradermally showed an improvement with this therapy. At the same time 5 of 12 patients progressed to invasive disease. This poor response rate suggests that this form of therapy should not be used with this disease.
D000287:Administration, Topical; D000328:Adult; D001761:Bleomycin / Q000008:administration & dosage*; D002278:Carcinoma in Situ / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007271:Injections, Intradermal; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D014846:Vulvar Neoplasms / Q000188:drug therapy*
D001761:Bleomycin